Royalty Pharma acquires royalty interest in AstraZeneca’s cliramitug for up to $425 million from Neurimmune
Royalty Pharma acquired a portion of Neurimmune’s royalty interest in AstraZeneca’s Phase 3 asset cliramitug for up to $425 million, including $125 million upfront. The deal secures a 3% to 4% royalty on worldwide net sales of cliramitug, a first-in-class treatment for ATTR-CM with peak sales estimated between $3 billion and $5 billion.
Key figures
- Deal Value Usd
- 425000000
- Royalty rate
- 3% to 4%
- Peak sales estimate
- $3 billion to $5 billion
- Upfront payment usd
- 125000000
- Milestone payment usd
- 175000000
- Subsequent payment usd
- 125000000
- Attr cm market size 2025
- $7 billion
AI analysis
Red flags2 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.